



SUVEN LIFE SCIENCES LTD

Regd. Off: SDE Serene Chambers, 6th floor, Road No.5, Banjara Hills, Hyderabad - 500 034

STATEMENT OF AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED MARCH 31, 2020.

		Rs. In Lakhs				
PART - I		STANDALONE				
Sl. No.	PARTICULARS	For the Quarter Ended			For the year ended	
		31/03/2020	31/12/2019	31/03/2019	31/03/2020	31/03/2019
		Ref note No.8	un-Audited	Ref note No.8	Audited	Audited
		(1)	(2)	(3)	(4)	(5)
1	Income					
	Revenue from operations	866.00	277.26	237.99	1,441.47	28,566.97
	Other Income	299.71	585.53	579.03	1,403.63	2,724.50
	Total income	1,165.71	862.79	817.02	2,845.10	31,291.47
2	Expenses					
	a) Cost of materials consumed	-	-	-	-	7,961.69
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	(929.28)
	c) Employee benefits expense	348.16	242.29	211.45	1,459.51	3,384.64
	d) Finance costs	23.21	9.81	29.07	54.03	190.26
	e) Depreciation and amortisation expense	105.24	85.50	80.18	416.87	1,078.97
	f) Manufacturing Expenses	-	-	-	-	4,825.55
	g) R & D Expenses	576.33	638.55	1,481.15	2,594.44	5,936.86
	h) Other Expenses	149.25	332.57	360.10	913.86	2,517.40
	Total expenses	1,202.19	1,308.72	2,161.95	5,438.71	24,966.09
3	Profit before exceptional items & Tax (1-2)	(36.48)	(445.93)	(1,344.93)	(2,593.61)	6,325.38
4	Exceptional Items	-	-	-	-	-
5	Profit before Tax (3-4)	(36.48)	(445.93)	(1,344.93)	(2,593.61)	6,325.38
6	Tax Expenses					
	a) Current tax	197.18	-	(298.50)	197.18	1,298.62
	b) Deferred tax	22.69	4.22	(108.68)	(1,415.47)	1,107.39
7	Net Profit/ (Loss) for the period/year(5-6)	(256.35)	(450.15)	(937.75)	(1,375.32)	3,919.37
8	Other Comprehensive Income					
8.a	(i) Items that will not be reclassified to profit or loss	(28.88)	(14.41)	10.59	(45.41)	(21.16)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	10.09	5.04	(3.70)	15.87	7.39
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	Total other Comprehensive Income	(18.79)	(9.37)	6.89	(29.54)	(13.77)
9	Total Comprehensive Income for the period (7+8)	(275.14)	(459.52)	(930.86)	(1,404.86)	3,905.60
10	Paid-up equity share capital	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00
11	Other Equity				37,494.53	38,899.39
12	Earning Per Share (EPS) (Face value of Rs.1/- each) :					
	a) Basic	(0.20)	(0.35)	(0.74)	(1.08)	3.08
	b) Diluted	(0.20)	(0.35)	(0.74)	(1.08)	3.08
		(not annualised)	(not annualised)	(not annualised)		

		Rs. In Lakhs				
		CONSOLIDATED				
Sl. No.	PARTICULARS	For the Quarter Ended			For the year ended	
		31/03/2020	31/12/2019	31/03/2019	31/03/2020	31/03/2019
		Ref note No.8	un-Audited	Ref note No.8	Audited	Audited
		(1)	(2)	(3)	(4)	(5)
1	Income					
	Revenue from operations	866.00	277.26	237.99	1,441.47	28,566.97
	Other Income	299.71	585.53	579.03	1,403.63	2,724.50
	Total income	1,165.71	862.79	817.02	2,845.10	31,291.47
2	Expenses					
	a) Cost of materials consumed	-	-	-	-	7,961.69
	b) Changes in inventories of finished goods, work-in-progress	-	-	-	-	(929.28)
	c) Employee benefits expense	433.21	332.26	282.14	1,740.91	3,649.29
	d) Finance costs	23.23	10.21	29.40	55.14	191.33
	e) Depreciation and	105.24	85.50	80.18	416.87	1,078.97
	f) Manufacturing Expenses	-	-	-	-	4,870.09
	g) R & D Expenses	2,783.77	2,370.78	4,397.26	10,322.64	11,894.33
	h) Other Expenses	156.21	341.18	378.36	949.62	2,559.44
	Total expenses	3,501.66	3,139.93	5,167.34	13,485.18	31,275.86
3	Profit before exceptional items , Tax (1-2)	(2,335.95)	(2,277.14)	(4,350.32)	(10,640.08)	15.60
4	Exceptional Items	-	-	-	-	-
5	Profit before Tax (3-4)	(2,335.95)	(2,277.14)	(4,350.32)	(10,640.08)	15.60
6	Tax Expenses					
	a) Current tax	197.18	-	(298.50)	197.18	1,298.62
	b) Deferred tax	22.69	4.22	(108.68)	(1,415.47)	1,107.39
7	Net Profit/ (Loss) for the period/year(5-6)	(2,555.82)	(2,281.36)	(3,943.14)	(9,421.79)	(2,390.41)
8	Other Comprehensive Income					
8.a	(i) Items that will not be reclassified to profit or loss	(28.89)	(14.41)	10.59	(45.41)	(21.16)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	10.10	5.03	(3.71)	15.87	7.39
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	Total other Comprehensive Income	(18.79)	(9.38)	6.88	(29.54)	(13.77)
9	Total Comprehensive Income for the period (7+ 8)	(2,574.61)	(2,290.74)	(3,936.26)	(9,451.33)	(2,404.18)
10	Paid-up equity share capital Face Value of the Share	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00
11	Other Equity	-	-	-	13,062.02	22,640.16
12	Earning Per Share (EPS) (Face value of Rs.1/- each) :					
	a) Basic	(2.01)	(1.79)	(3.10)	(7.40)	(1.88)
	b) Diluted	(2.01)	(1.79)	(3.10)	(7.40)	(1.88)
		(not annualised)	(not annualised)	(not annualised)		

NOTES:-

1.The above results were reviewed by Audit Committee of the Board and approved by the Board of Directors' at their Meeting held on June 05, 2020.

2.The National Company Law Tribunal, Hyderabad Bench vide its order dated January 06,2020 has approved the scheme of arrangement for demerger of CRAMS undertaking of the Company to Suven Pharmaceuticals Limited (SPL) with effect from October 01, 2018 (the appointed date). The Scheme became effective from October 01, 2018. Pursuant to the Scheme, all the assets, liabilities, income and expenses of the CRAMS undertaking have been transferred to SPL from the appointed date.

Consequently, the figures in Column (5) represent Demerged Undertaking & Research and development Business for the period 01-04-2018 to 30-09-2018 (i.e. PRE DEMERGER) and figures for the subsequent period 01-10-2018 to 31-03-2019 (POST DEMERGER) in Column (5) are of Research and development Business as a result of demerger of CRAMS undertaking of the Company to Suven Pharmaceuticals Limited (SPL) with effect from October 01, 2018. To that extent current quarter and year numbers are not comparable with previous periods presented.

3.The Company (SLSL) has to transfer the statutory and regulatory licenses with in India and Outside India so as to enable SPL to carry on the business in its name. The process of obtaining the approvals from all departments is a lengthy process. In order to maintain the continuity of the business during these statutory approvals period, the Company is continuing the CRAMS business in its own name on behalf of SPL. However, all such operations were recorded in the books of SPL, the same may be continued till the migration of all licenses in the name of SPL.

4. The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.

5. The Company is in the process of evaluating the impact of newly introduced Sec.115BAA of the Taxation Laws (Amendments) Ordinance , 2019.

6.The COVID-19 impact on the business and going concern assumption of SLSL and its subsidiary:
COVID-19 had not impacted the company's research operations, which includes our subsidiary, Suven Neurosciences, Inc. However, we are foreseeing certain delays in enrollment of ongoing phase 2 clinical studies conducted in the USA.

7. Impact of Fire accident that occurred subsequent to the Balance Sheet date:

On April 26, 2020 fire incident occurred in one of the buildings in our research facilities located at Jeedimetla, Hyderabad. This incident has no major impact on our regular operations, however early stage drug discovery is impacted. The company's properties are fully covered through insurance policies. The replacement cost of damaged equipment is being assessed by the surveyors.

8.The figures for the quarters ended March 31, 2020 and March 31, 2019 are the balancing figures between audited figures in respect of the full financial years and the published unaudited year to date figures upto third quarter of the respective financial years. Also, the figures upto the end of the third quarter were only reviewed and not subjected to audit.

9. The corresponding previous period figures have been regrouped / reclassified where ever necessary.

10.The above is an extract of the detailed format of Quarterly/ Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Annual Financial Results are available on the websites of the stock exchanges(s) and the listed entity. (www.bseindia.com and www.nseindia.com) and company's website www.suven.com

For SUVEN LIFE SCIENCES LTD

**Place : Hyderabad
Date : June 05, 2020**

**VENKAT JASTI
Chairman & CEO
DIN: 00278028**